Moderna (MRNA) Competitors

Moderna (NASDAQ:MRNA) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Which has better earnings & valuation, MRNA or ARGX?

argenx has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$3.14B	3.45	-$3.56B	-$8.73	-3.21
argenx	$2.58B	13.69	-$295.05M	$16.21	35.68

Is MRNA or ARGX more profitable?

argenx has a net margin of -2.11% compared to Moderna's net margin of -110.04%. argenx's return on equity of -1.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-110.04%	-28.74%	-21.83%
argenx	-2.11%	-1.45%	-1.29%

Does the media prefer MRNA or ARGX?

In the previous week, argenx had 1 more articles in the media than Moderna. MarketBeat recorded 23 mentions for argenx and 22 mentions for Moderna. argenx's average media sentiment score of 1.17 beat Moderna's score of 0.96 indicating that argenx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
argenx	16 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, MRNA or ARGX?

Moderna has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, argenx has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Does the MarketBeat Community prefer MRNA or ARGX?

argenx received 447 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.52% of users gave argenx an outperform vote while only 53.33% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Moderna	Outperform Votes 216 53.33%	Underperform Votes 189 46.67%
argenx	Outperform Votes 663 67.52%	Underperform Votes 319 32.48%

Do analysts prefer MRNA or ARGX?

Moderna presently has a consensus target price of $53.95, indicating a potential upside of 92.74%. argenx has a consensus target price of $698.11, indicating a potential upside of 20.72%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04
argenx	0 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	3.04

Do insiders and institutionals hold more shares of MRNA or ARGX?

75.3% of Moderna shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

argenx beats Moderna on 13 of the 19 factors compared between the two stocks.